

Prior authorization requirements for Chimeric antigen receptor T-cell therapy

Prior authorization (PA) requirements changed for Chimeric antigen receptor T-cell (CAR T) therapy, including immunotherapy and all inpatient stays covered by Summit Community Care.

CAR T therapy is currently represented by the following codes:

- Kymriah™ (Tisagenlecleucel) — up to 250 million CAR-positive viable T-cells, including leukapheresis and dose-preparation procedures, per infusion (Q2040)
- Axicabtagene Ciloleucel — up to 200 million autologous anti-CD19 CAR T-cells, including leukapheresis and dose-preparation procedures, per infusion (new code effective April 1, 2018: Q2041)

CAR T therapy in any form, regardless of the place of service in which it is given, requires PA.

Please use one of the following methods to submit a request:

- **Web:** <https://www.availity.com>
- **Fax:**
 - Behavioral/mental health: 1-877-434-7578
 - Nonbehavioral/mental health: 1-501-224-1355
- **Phone:** 1-844-462-0022

Not all PA requirements are listed here. PA requirements are available to contracted and noncontracted providers on our provider website at <https://www.summitcommunitycare.com/provider>. Providers may also call us at 1-844-462-0022 for PA requirements.